MicroRNA-29b inhibits diabetic nephropathy in db/db mice. - Wikidata - awgldk - TriplyDB

MicroRNA-29b inhibits diabetic nephropathy in db/db mice.

MicroRNA-29b inhibits diabetic nephropathy in db/db mice.

http://www.wikidata.org/entity/Q38692630

about

TGF-β/Smad signaling in renal fibrosis MicroRNAs in fibrosis: opportunities and challenges Regulatory Mechanisms of the Molecular Pathways in Fibrosis Induced by MicroRNAs Mini-review: emerging roles of microRNAs in the pathophysiology of renal diseases Systems biology combining human- and animal-data miRNA and mRNA data identifies new targets in ureteropelvic junction obstruction Serum levels of WNT1-inducible signaling pathway protein-1 (WISP-1): a noninvasive biomarker of renal fibrosis in subjects with chronic kidney disease.The role of microRNAs in diabetic nephropathy.MicroRNAs in renal fibrosis.Different regulation of miR-29a-3p in glomeruli and tubules in an experimental model of angiotensin II-dependent hypertension: potential role in renal fibrosis.MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.Uremic Toxicity of Advanced Glycation End Products in CKD.Treatment of renal fibrosis by rebalancing TGF-β/Smad signaling with the combination of asiatic acid and naringenin.Long Noncoding RNA Arid2-IR Is a Novel Therapeutic Target for Renal Inflammation MicroRNAs as novel therapeutic targets to treat kidney injury and fibrosis.Inhibition of the processing of miR-25 by HIPK2-Phosphorylated-MeCP2 induces NOX4 in early diabetic nephropathy.A Systematic Study of Dysregulated MicroRNA in Type 2 Diabetes Mellitus.Diabetic nephropathy--emerging epigenetic mechanisms.Mesenchymal stem cells as novel micro-ribonucleic acid delivery vehicles in kidney disease.miRNAs: early prognostic biomarkers for Type 2 diabetes mellitus?miR-29 Regulates Type VII Collagen in Recessive Dystrophic Epidermolysis Bullosa.miR-29b promotes skin wound healing and reduces excessive scar formation by inhibition of the TGF-β1/Smad/CTGF signaling pathway.MicroRNA-29: A Crucial Player in Fibrotic Disease.Epigenetics of kidney disease.Epigenetic factors as drivers of fibrosis in systemic sclerosis.MicroRNAs in the pathogenesis of type 2 diabetes: new research progress and future direction.MicroRNAs in Renal Diseases: A Potential Novel Therapeutic Target.Reciprocal regulation of miR-214 and PTEN by high glucose regulates renal glomerular mesangial and proximal tubular epithelial cell hypertrophy and matrix expansion.TGF-β Mediates Renal Fibrosis via the Smad3-Erbb4-IR Long Noncoding RNA Axis.Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD.Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice.MicroRNA-29b inhibits peritoneal fibrosis in a mouse model of peritoneal dialysis.MicroRNA and Microvascular Complications of Diabetes.Noncoding RNAs as therapeutic targets in early stage diabetic kidney disease

P2860

Q26851198-E918E424-0232-4FD4-BE14-32650D346C58 Q28067380-C1714956-F214-4A5A-BAED-52B967B77A2D Q28072792-9E69EA9E-3136-4F98-BFD1-A545ADEE1C6E Q28354033-A062B0EF-05CF-49AB-B5BF-CAEA18B1C5EA Q30253062-731B860B-3272-405C-A0BF-B2D88D3F02BF Q33850279-A6D595B4-8AA6-4F08-9453-EA6BCEEF453E Q34195411-69BF596C-C11B-477C-AEE2-776B18589D70 Q35104478-FEFD371F-7647-4916-9A45-8B11A75CCCBE Q35877447-BEBCBC1A-25F7-4CFC-B57F-8A9B808A8C02 Q36166755-8C75F244-622F-4B16-9AC8-53DA345C7933 Q36514906-9EED1822-FCF4-4D72-A68A-936BD282E417 Q36545653-3831BFF7-F621-4BB5-BB26-8EBDEA72F6B9 Q36756684-0BAA3BC7-DB41-4691-8393-08DD4B68ECA7 Q37211825-8B6DB4A9-CA05-43FF-B57C-764337748E29 Q37493523-C0AAC77B-F268-4297-9277-6D70AE3172A1 Q37728970-C294FBC2-4A14-432F-B45F-CD4189EA547A Q38227252-5FA19909-B028-4B0C-8FB0-D0852175586B Q38599408-15C8340A-63BA-449B-B14B-287BD3177C7A Q38600595-570A2AB2-6FB5-4316-A5CA-2FBB19748BAF Q38763040-A39230FE-CCA4-44BE-8894-2C863E78DAEB Q38769935-FDF5DFB8-BD15-48B7-9E32-87A43BAC13BB Q39107249-600F0D2A-43A6-43DF-88E3-1D66BD6EF755 Q39175636-9ED120F3-F42D-4048-ACCC-758563D6C184 Q39200920-7A1B3619-53C3-4A58-8901-88C0B7675B8C Q46308323-87834B64-901D-4C65-A8C3-E296C4265435 Q47654194-FF442822-6647-4B5C-BE25-E28EC27ED17F Q47828965-E3185096-EB6C-4E57-B3CF-C1617759A866 Q48611625-066D83CD-44D3-4E38-A717-32EF1EA37546 Q50063239-D5D3A9CC-85FA-4625-A1F9-A5FE1E4264E7 Q51165884-794E5246-E78A-4F77-ACBF-F23A6034B7A5 Q53797400-3BE0E4D7-B8A4-447D-9ABF-ED44B19FC53A Q55262853-6DD4D8DB-E73A-47C9-9A1C-5B9C186BB2E1 Q58795409-A4A8DE93-0D61-4C92-98CB-A6444D5079B4

P2860

MicroRNA-29b inhibits diabetic nephropathy in db/db mice.

http://www.wikidata.org/entity/Q38692630

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

MicroRNA-29b inhibits diabetic nephropathy in db/db mice.

@en

type

label

MicroRNA-29b inhibits diabetic nephropathy in db/db mice.

@en

prefLabel

MicroRNA-29b inhibits diabetic nephropathy in db/db mice.

@en

P1433

Q38692630-62A7D746-A284-4088-9D41-1515DCE7B525

P1476

Q38692630-45B0BD3A-C595-4368-AA6A-0AB3FD671C87

P2093

Q38692630-26E8FC5D-EC2D-4F16-AC0E-20E1FDFE585A

Q38692630-5F9E2608-0208-4FD4-A125-604D5FA08AFF

Q38692630-AED55619-D977-4E75-BD57-B6E2AF690CED

Q38692630-C63F61E6-876E-469F-89B1-960CED539FF4

P2860

Q38692630-07335286-C9D6-4038-A5D2-C133D6DFEFE7

Q38692630-0747897B-1C41-4386-A604-93BC9E9775D2

Q38692630-09E974AD-67DD-43DE-B600-5FF5A3976CDA

Q38692630-115D27F6-F050-4994-9871-24141AE327C8

Q38692630-14FFA30E-BC18-4706-AC2E-97C1FB15F75D

Q38692630-238F869D-7D3A-401B-83E1-3EFA49ACCDE9

Q38692630-2A5115B3-0E6C-4840-A7DB-5FA345522F6D

Q38692630-2BE2317D-71EF-4716-9D6D-6AE440DD3FFE

Q38692630-2F6E048B-6BE6-4AD2-A965-A56C38B9FCED

Q38692630-36CCDC6D-51D7-48CD-8CC4-F4C0D786AD25

P304

Q38692630-C3960E3D-1ED9-4CD7-B985-54CF12548B28

P31

Q38692630-69A7275C-0E45-4FDE-AD1A-1086784AFDD6

P356

Q38692630-03E553CC-66A9-4922-9B82-DFB6447FB09A

P433

Q38692630-0CE8C84A-521A-4278-AC69-A646D349B9BF

P478

Q38692630-8649E538-2F5D-44B1-8FA5-6B7DB824A8AB

P50

Q38692630-14B0EC3D-3EFF-4320-9837-9BCB91233E1E

Q38692630-4ED1A311-576B-4057-8DCF-7D49B4B7A4A3

Q38692630-BD8EC312-BB47-45BE-8865-C947B6A2C7EC

P577

Q38692630-26482CAE-E2E7-435B-B7F9-2C0DB4B97DAC

P698

Q38692630-A45B38EB-33A3-427F-ABC0-AB8665AA9514

P921

Q38692630-3AB191DB-4390-4482-828E-599D3382AFCB

P932

Q38692630-C12E5C1F-2936-4E74-9B82-22694B0B20ED

P356

P1433

Molecular Therapy

P1476

MicroRNA-29b inhibits diabetic nephropathy in db/db mice.

@en

P2093

Arthur Ck Chung

http://www.w3.org/2001/XMLSchema#string

Xiang Zhong

http://www.w3.org/2001/XMLSchema#string

Xiao R Huang

http://www.w3.org/2001/XMLSchema#string

Yongke You

http://www.w3.org/2001/XMLSchema#string

P2860

A novel transcription factor, T-bet, directs Th1 lineage commitment

High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells

Sp1 and Smad proteins cooperate to mediate transforming growth factor-beta 1-induced alpha 2(I) collagen expression in human glomerular mesangial cells

Identification of a novel type 1 diabetes susceptibility gene, T-bet

TGF-beta: a crucial component of the pathogenesis of diabetic nephropathy

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis

Streptozotocin-induced diabetic nephropathy in rats: the role of inflammatory cytokines.

Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.

Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes.

P304

842-853

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2013.235

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24445937

http://www.w3.org/2001/XMLSchema#string

P921

P932

3982502

http://www.w3.org/2001/XMLSchema#string